Market cap below net current asset value
Graham's strictest test. If market cap is below net current asset value (current assets minus all liabilities), buying the whole company and liquidating would still leave money over. Almost no passing stocks is normal.
This lens has no Track Record summary yet — only scored signals are shown on the Track Record page. The table below is the current pass list.
| Stock | NCAV | Market cap | NCAV / market cap | Price since latest filing |
|---|---|---|---|---|
| Vipshop Holdings Ltd (VIPS) | $5.2B | $1.3B | 3.97 | -5.1% · 13F Jul 1 |
| NOAH HOLDINGS LTD (NOAH) | $4.6B | $2.4B | 1.90 | -36.4% · 13F Jul 1 |
| Zhihu Inc. (ZH) | $3.4B | $758.5M | 4.50 | -18.6% · 13F Jul 1 |
| ATRenew Inc. (RERE) | $2.8B | $668.2M | 4.14 | +0.0% · 13F Jul 1 |
| SPYRE THERAPEUTICS INC (SYRE) | $715.2M | $682.5M | 1.05 | +5.5% · 13F Jul 1 |
| BICYCLE THERAPEUTICS PLC-ADR (BCYC) | $575.3M | $264.6M | 2.17 | -24.0% · 13F Jul 1 |
| NOVA LTD. (NVMI) | $368.5M | $11.0M | 33.58 | -38.6% · 13F Jul 1 |
| Gemini Space Station, Inc. (GEMI) | $345.3M | $115.7M | 2.99 | -55.2% · 13F Jul 1 |
| STANDARD BIOTOOLS INC. (LAB) | $310.8M | $236.6M | 1.31 | -15.7% · Form 4 Nov 6 |
| MAPLIGHT THERAPEUTICS INC (MPLT) | $303.5M | $67.0M | 4.53 | -45.9% · 13D Aug 19 |
| REPLIGEN CORP (RGEN) | $293.8M | $10.7M | 27.54 | +16.7% · 13F Jul 1 |
| Nuvation Bio Inc. (NUVB) | $282.4M | $1.6M | 173.35 | -28.0% · 13F Jul 1 |
| LENZ THERAPEUTICS INC (LENZ) | $279.9M | $100.6M | 2.78 | -39.6% · 13F Jul 1 |
| EYEPOINT INC (EYPT) | $270.8M | $27.8K | 9727.62 | -97.8% · 13F Jul 1 |
| BIOAGE LABS INC (BIOA) | $264.0M | $213.4M | 1.24 | -79.0% · 13F Jul 1 |
| CAMTEK LTD (CAMT) | $254.2M | $6.3M | 40.15 | -38.9% · 13F Jul 1 |
| Damora Therapeutics, Inc. (DMRA) | $240.3M | $30.0M | 8.01 | +9.2% · Form 4 Sep 29 |
| Altimmune, Inc. (ALT) | $223.2M | $188.5M | 1.18 | -51.4% · 13F Jul 1 |
| Sionna Therapeutics, Inc. (SION) | $222.3M | $159.8M | 1.39 | -49.0% · 13D Sep 22 |
| Invivyd, Inc. (IVVD) | $212.1M | $103.7M | 2.05 | -40.0% · 13F Jul 1 |
| LEXEO THERAPEUTICS INC (LXEO) | $166.4M | $164.2M | 1.01 | -35.8% · 13F Jul 1 |
| X4 PHARMACEUTICALS INC (XFOR) | $157.4M | $142.1M | 1.11 | +2.3% · Form 4 Oct 20 |
| PROTARA THERAPEUTIC INC (TARA) | $146.4M | $107.9M | 1.36 | -42.6% · 13F Jul 1 |
| Veradermics, Inc (MANE) | $143.3M | $107.2M | 1.34 | +27.6% · 13D Aug 24 |
| EVOMMUNE INC (EVMN) | $134.1M | $41.8M | 3.21 | -45.2% · 13F Jul 1 |
| PALISADE BIO INC (PALI) | $129.3M | $66.2M | 1.95 | -32.2% · Form 4 Oct 6 |
| ADICET BIO INC (ACET) | $127.8M | $24.7M | 5.18 | -67.8% · 13F Jul 1 |
| PepGen Inc. (PEPG) | $124.5M | $101.8M | 1.22 | +114.4% · 13F Jul 1 |
| SPYGLASS PHARMA INC (SGP) | $98.6M | $72.1M | 1.37 | +61.5% · 13F Jul 1 |
| TENAX THERAPEUTICS INC (TENX) | $97.1M | $72.9M | 1.33 | -19.3% · Form 4 Oct 22 |
| Caribou Biosciences, Inc. (CRBU) | $92.0M | $41.6M | 2.21 | -80.6% · 13F Jul 1 |
| Rafael Holdings, Inc. (RFL) | $41.0M | $33.0M | 1.24 | -75.8% · 13F Jul 1 |
More in Financial Screens: Buffett · Growth · Graham · Piotroski · Greenblatt Magic Formula · Lynch PEG · Dividend Growth · Cash Flow (FCF) · Deep Value (Templeton) · O'Neil CAN SLIM · Neff Total Return Ratio · Gross Profitability (Novy-Marx) · Earnings Quality (Cash Conversion) · Shareholder Yield · Earnings Stability.
For education only — not investment advice. Past records do not guarantee future results. How each number is measured: Methodology.
Buffett · Track Record: how 13F signals scored · Practice timing
One email a week: the week’s new filings and research. Subscribe free
← Shareholder Yield · Earnings Stability →
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.